Emerging markets are reshaping the global pharmaceutical landscape. According to IQVIA, emerging markets are projected to account for over 30% of global pharmaceutical spending by 2026, with growth rates consistently outpacing developed markets.
In the pharmaceutical industry, compliance is not merely a regulatory checkbox; it is the bedrock of patient safety, market access, and international credibility. According to the World Health Organization, substandard and falsified medical products cause an estimated 267,000 deaths annually in low- and middle-income countries alone.
Across the world, marginalized communities face a persistent challenge that extends beyond the availability of medicines: the lack of awareness about preventable diseases, early symptoms, and available treatments.
In global pharmaceuticals, filing a dossier is the starting line, not the finish line. True regulatory strength is defined by how consistently and efficiently a company secures market authorizations across different regulatory environments.
Chronic diseases represent the most significant health challenge of the 21st century. According to the World Health Organization, cardiovascular diseases (CVDs) are the leading cause of death globally, claiming an estimated 17.9 million lives each year.
When a patient takes a medication, they trust that it will help them, not harm them. Behind that trust lies a complex, continuous process that operates silently in the background, monitoring every medicine throughout its lifecycle. This process is called pharmacovigilance, and its importance cannot be overstated.
Despite decades of progress in medicine and public health, women's health access remains one of the most urgent challenges of our time. According to the World Health Organisation, nearly 800 women die every day from preventable causes related to pregnancy and childbirth, a staggering statistic that represents not just medical failure, but systemic inequity.
Across developing countries, there is a staggering gap between healthcare needs and available resources. According to the latest WHO-World Bank report, 2 billion people worldwide face financial hardship due to healthcare costs, while the situation in sub-Saharan Africa is particularly acute: the continent imports a significant majority of its pharmaceuticals, leaving it highly vulnerable to global supply chain disruption